Cortendo is a global biopharmaceutical company focused on orphan endocrine disorders and cortisol inhibition. Its lead investigational drug, COR-003 (levoketoconazole), is being studied in the global Phase 3 SONICS trial for endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the EMA and the FDA. The company intends to independently commercialize its orphan/endocrine assets in key markets and to partner non-strategic opportunities such as diabetes at relevant stages. Cortendo is incorporated in Sweden and based in the United States. Recent financings — including the latest private placement — are intended to strengthen the company’s ability to drive enrollment in the Phase 3 trial and to support partnering efforts.

Total raised

$26M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2015